- Home
- PTIX vs SNOA Comparison
PTIX vs SNOA Comparison
Compare PTIX & SNOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTIX
- SNOA
- Stock Information
- Founded
- PTIX 1994
- SNOA 1999
- Country
- PTIX United States
- SNOA United States
- Employees
- PTIX N/A
- SNOA N/A
- Industry
- PTIX Biotechnology: Pharmaceutical Preparations
- SNOA Biotechnology: Pharmaceutical Preparations
- Sector
- PTIX Health Care
- SNOA Health Care
- Exchange
- PTIX Nasdaq
- SNOA Nasdaq
- Market Cap
- PTIX 3.7M
- SNOA 3.7M
- IPO Year
- PTIX 2016
- SNOA 2007
- Fundamental
- Price
- PTIX $0.70
- SNOA $2.53
- Analyst Decision
- PTIX
- SNOA
- Analyst Count
- PTIX 0
- SNOA 0
- Target Price
- PTIX N/A
- SNOA N/A
- AVG Volume (30 Days)
- PTIX 292.0K
- SNOA 366.2K
- Earning Date
- PTIX 11-14-2024
- SNOA 02-06-2025
- Dividend Yield
- PTIX N/A
- SNOA N/A
- EPS Growth
- PTIX N/A
- SNOA N/A
- EPS
- PTIX N/A
- SNOA N/A
- Revenue
- PTIX N/A
- SNOA $13,547,000.00
- Revenue This Year
- PTIX N/A
- SNOA $23.89
- Revenue Next Year
- PTIX N/A
- SNOA $25.45
- P/E Ratio
- PTIX N/A
- SNOA N/A
- Revenue Growth
- PTIX N/A
- SNOA 11.81
- 52 Week Low
- PTIX $0.45
- SNOA $2.44
- 52 Week High
- PTIX $1.87
- SNOA $9.40
- Technical
- Relative Strength Index (RSI)
- PTIX 55.96
- SNOA 40.15
- Support Level
- PTIX $0.50
- SNOA $2.61
- Resistance Level
- PTIX $0.56
- SNOA $3.25
- Average True Range (ATR)
- PTIX 0.06
- SNOA 0.21
- MACD
- PTIX 0.01
- SNOA -0.02
- Stochastic Oscillator
- PTIX 84.31
- SNOA 11.11
About PTIX Protagenic Therapeutics Inc.
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.
About SNOA Sonoma Pharmaceuticals Inc.
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.